SINOVAC's Varicella Vaccine Approved for Registration in Indonesia

BEIJING, Nov. 7, 2025 — SINOVAC Biotech Ltd. ("SINOVAC" or the "Company"), a leading global provider of biopharmaceutical products, today announced that its live attenuated varicella vaccine, produced by SINOVAC (Dalian) Vaccine Technology Co., Ltd., has been granted marketing authorization by the Indonesian authorities (BPOM). To date, the vaccine has received regulatory approvals in multiple international markets, including Indonesia, Argentina, Peru, and Lebanon.

As the first and currently only varicella vaccine from China to receive World Health Organization (WHO) Prequalification, the product has been distributed to nearly 20 countries and regions, with cumulative global shipments exceeding 20 million doses.

The SINOVAC varicella vaccine is developed using the proprietary human diploid cell line (SV-1) and manufactured under B+A grade cleanliness standards. The formulation is notably free of antibiotics, gelatin, and human serum albumin, minimizing the risk of potential allergic reactions. Additionally, the vaccine is designed with an osmotic pressure profile similar to human fluids, which has been shown to reduce injection-site pain and localized adverse reactions.

A recent head-to-head clinical study comparing SINOVAC's vaccine with another WHO-prequalified international varicella vaccine demonstrated that SINOVAC's candidate met the non-inferiority criteria for immunogenicity. Furthermore, the study reported a superior safety profile compared to the control group. These findings strengthen the evidence-based clinical framework supporting the vaccine's global application and provide robust data for public health decision-making.

The approval in Indonesia a market with rigorous quality standards and specific Halal compliance requirements underscores SINOVAC's comprehensive capabilities in process control, quality management, and religious compliance. This milestone further expands SINOVAC's international footprint and contributes to the global supply of high-quality varicella vaccines, intended to reduce the public health burden of associated infectious diseases worldwide.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.

The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.

SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.

Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines,recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.

With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.

For more information, please see the Company’s website at www.sinovac.com.